Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)

Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)

Predictive values of IC₅₀ in mM (FFAs) for vanadium compounds and <i>in vivo</i> observations IC₅₀ in mM (FFAs) and decreasing blood glucose level. by Elena V. Fedorova (603922)

“…<p>Predictive values of IC₅₀ in mM (FFAs) for vanadium compounds and <i>in vivo</i> observations IC₅₀ in mM (FFAs) and decreasing blood glucose level.…”

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Pretreatment with SDG prevents iron induced decrease in H9c2 cell size. by Stephanie Puukila (568109)

3D snapshots of the tumor system with single-agent BHQ880 treatment at (a) time step 40, (b) time step 50 and (c) time step 120. by Minna Qiao (836556)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Definitions of the features selected [50]. by Yu Zhang (12946)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Predicted cylindrical cavity pressure as a function of saturation for two clay contents (16 and 50%) and for a range of cavity radii (1 to 5 mm). by Siul Ruiz (757454)